期刊文献+

帕罗西汀与氯硝西泮治疗广泛性焦虑症对照研究 被引量:2

A controlled study of paroxetine and flunipam in the treatment of generalized anxiety
暂未订购
导出
摘要 目的探讨帕罗西汀与氯硝西泮治疗广泛性焦虑症的疗效与不良反应。方法将63例广泛性焦虑障碍患者随机分为两组。研究组32例给予帕罗西汀治疗;对照组31例给予氯硝西泮治疗,两组疗程均为6w。两组于治疗前和治疗第3,6w末采用焦虑自评量表、汉密顿焦虑量表和副反应量表评定临床疗效与副反应,并进行比较。结果帕罗西汀与氯硝西泮对广泛性焦虑障碍均有明显疗效。两组组内治疗前与治疗第3,6w末汉密顿焦虑量表、焦虑自评量表减分率比较有极显著性差异(P<0.01);两组间汉密顿焦虑量表减分率比较无显著性差异(P>0.05),焦虑自评量表减分率差异有极显著性(P<0.01);治疗第6w末两组副反应量表评分有极显著性差异(P<0.01)。结论帕罗西汀治疗广泛性焦虑障碍安全有效,患者耐受性好,副反应轻微。 Objective To explore the efficacies and side effects of paroxetine and flunipam in the treatment of generalized anxiety. Methods 63 patients with generalized anxiety were randomly divided into research (n=32, took paroxetine) and control(n=32,did flunipam) group for 6 weeks. Efficacies and side effects were assessed and compared using the Self-rating Anxiety Scale(SAS), the Hamilton Anxiety Scale(HAMA) and the Treatment Emergent Symptom Scale(TESS) before treatment and at the ends of the 3rd and 6th week treatment. Results Both paroxetine and flunipam had better efficacies in the treatment of gener alized anxiety. There were the most significant differences in score-reducing rates of the SAS and HAMA between pre-treatment and ends of the 3rd and 6th week for both 2 groups(P〈0.01) ; there was no significant differnce in score-reducing rate of the HAMA(P〉0.05) and was the most significant difference in that of the SAS(P〈0.01) between the 2 groups, at the end of the 6th week, there was the most significant differnce in the score of the TESS between the 2 groups(P〈0.01). Conclusion Paroxetine is effective and safe and has well tolerance and milder side effects in the treatment of generalized anxiety.
出处 《临床心身疾病杂志》 CAS 2006年第3期169-170,共2页 Journal of Clinical Psychosomatic Diseases
关键词 帕罗西汀 氯硝西泮 广泛性焦虑症 焦虑自评量表 汉密顿焦虑量表 Paroxetine flunipam generalized anxiety the SAS the HAMA
  • 相关文献

参考文献1

  • 1陈彦方.CCMD-3相关精神障碍的治疗与护理[M].第1版.济南:山东科学技术出版社,2004:280

同被引文献20

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部